AtriCure Inc (ATRC)
23.14
+0.51
(+2.25%)
USD |
NASDAQ |
May 17, 16:00
23.07
-0.07
(-0.30%)
After-Hours: 20:00
AtriCure Research and Development Expense (Annual): 73.92M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 73.92M |
| December 31, 2022 | 57.34M |
| December 31, 2021 | 48.51M |
| December 31, 2020 | 43.07M |
| December 31, 2019 | 41.23M |
| December 31, 2018 | 34.72M |
| December 31, 2017 | 34.14M |
| December 31, 2016 | 35.82M |
| December 31, 2015 | 25.74M |
| December 31, 2014 | 18.60M |
| Date | Value |
|---|---|
| December 31, 2013 | 13.44M |
| December 31, 2012 | 12.15M |
| December 31, 2011 | 11.86M |
| December 31, 2010 | 11.53M |
| December 31, 2009 | 11.41M |
| December 31, 2008 | 10.61M |
| December 31, 2007 | 10.99M |
| December 31, 2006 | 12.22M |
| December 31, 2005 | 9.109M |
| December 31, 2004 | 4.422M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
41.23M
Minimum
2019
73.92M
Maximum
2023
52.81M
Average
48.51M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Alphatec Holdings Inc | 70.12M |
| Intuitive Surgical Inc | 998.80M |
| LeMaitre Vascular Inc | 16.97M |
| iRhythm Technologies Inc | 60.24M |
| RxSight Inc | 29.05M |